title: [Therapeutic Strategies. Cardiovascular risk and dyslipidemia in elderly and women].
abstract: The management of cardiovascular risk and dyslipidemia are justified in guidelines. In the elderly, when they are in primary prevention, recommendations are controversial, even if there is evidence in reducing morbidity. In secondary prevention, between 65 and 85 years, there is enough evidence to recommend statins. The decision to start or to continue further treatment must be complemented by comprehensive assessment of the risk-benefit factor. In elderly patients we have to support in decision-making, we take clinical judgment and not just the age criteria. In women the risk is underestimated and may be untreated. The recomendations are the same as in men. During pregnancy there are particular recommendations.
authors.affiliation: Servicio de Medicina Interna, Unidad de Lípidos y Riesgo Vascular, Unidad Funcional Fractura de Fémur, Althaia, Xarxa Assistencial i Universitària de Manresa, Barcelona, España. Electronic address: cmorales@althaia.cat.
authors.forename: Clotilde
authors.initials: C
authors.lastname: Morales
authors.forename: Meritxell
authors.initials: M
authors.lastname: Royuela
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003657:Decision Making; D050171:Dyslipidemias / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology / Q000628:therapy; D011322:Primary Prevention / Q000379:methods; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods; D012737:Sex Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Ancianos; Cardiovascular risk; Clinical judgment; Dislipidemias; Dyslipidemia; Elderly; Juicio clínico; Mujeres; Riesgo cardiovascular; Women